New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza

 
• By Alexandra Shimmings
  
OvarianCancer_1200x675
Cures are elusive in first-line ovarian cancer, but two PARP inhibitors improved progression-free surivival. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D